English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

In cis TP53 and RAD51C pathogenic variants may predispose to sebaceous gland carcinomas (advance online)

MPS-Authors
/persons/resource/persons180889

Le Duc,  Diana
Department of Evolutionary Genetics, Max Planck Institute for Evolutionary Anthropology, Max Planck Society;

External Ressource
No external resources are shared
Fulltext (public)

LeDuc_In-cis-TP53_EurJHumGen_2020.pdf
(Publisher version), 2MB

Supplementary Material (public)
There is no public supplementary material available
Citation

Le Duc, D., Hentschel, J., Neuser, S., Stiller, M., Meier, C., Jäger, E., et al. (2020). In cis TP53 and RAD51C pathogenic variants may predispose to sebaceous gland carcinomas (advance online). European Journal of Human Genetics. doi:10.1038/s41431-020-00781-x.


Cite as: http://hdl.handle.net/21.11116/0000-0007-A13D-F
Abstract
Pathogenic variants in TP53 have been classically thought to cause Li-Fraumeni syndrome (LFS), a cancer predisposition with high risks for various childhood- and adult-onset malignancies. However, increased genetic testing has lately revealed, that pathogenic variant carriers exhibit a broader range of phenotypes and that penetrance may be dependent both on variant type and modifiers. Using next generation sequencing and short tandem repeat analysis, we identified germline pathogenic variants in TP53 and RAD51C located in cis on chromosome 17 in a 43-year-old male, who has developed a rare sebaceous gland carcinoma (SGC) but so far no tumors of the LFS spectrum. This course mirrors a Trp53-Rad51c-double-mutant cis mouse-model, which similarly develops SGC, while the characteristic Trp53-associated tumor spectrum occurs with significantly lower frequency. Therefore, we propose that co-occurent pathogenic variants in RAD51C and TP53 may predispose to SGC, reminiscent of Muir-Torre syndrome. Further, this report supports the diversity of clinical presentations associated with germline TP53 alterations, and thus, the proposed expansion of LFS to heritable TP53-related cancer syndrome.